Cargando…
Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China
Homologous recombination deficiency (HRD) is an approved predictive biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer. However, the proportion of positive HRD in the real world and the relationship between HRD status and PARPi in Chinese ovarian cancer patients remain u...
Autores principales: | Ni, Jing, Guo, Wenwen, Zhao, Qian, Cheng, Xianzhong, Xu, Xia, Zhou, Rui, Gu, Hongyuan, Chen, Chen, Chen, Xiaoxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779205/ https://www.ncbi.nlm.nih.gov/pubmed/35070965 http://dx.doi.org/10.3389/fonc.2021.746571 |
Ejemplares similares
-
Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
por: Ni, Jing, et al.
Publicado: (2021) -
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
por: Batalini, Felipe, et al.
Publicado: (2023) -
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018) -
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair
por: Bryant, Helen E., et al.
Publicado: (2006) -
Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)